Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / Jun / Fingerprinting mAbs
Discovery & Development Analytical Science

Fingerprinting mAbs

Scientists find a way to ‘fingerprint’ the structure of a monoclonal antibody

By Stephanie Vine 06/02/2015 1 min read

Share

Precisely measuring the structural configuration of monoclonal antibodies (mAbs) is important when it comes to safety and efficacy. To that end, Robert Brinson, a chemist at the National Institute of Standards and Technology (NIST), and his team have used a technique called near-magnetic resonance (NMR) spectroscopy to measure the fingerprint of mAbs (1). Brinson explains NMR fingerprinting in more detail.

What are the challenges to fingerprinting mAbs?
The intact mAb we looked at is around 150,000 Daltons, and the Fc and Fab fragments are 50,000 Daltons. For comparison, aspirin, the classic small-molecule drug, is 180 Daltons. Neupogen, a biologic, is 18,800 Daltons. A small-molecule drug can be easily characterized, but this is not the case for a complex biotherapeutic protein. While the primary amino acid sequence may be known, one protein batch can be safe and another toxic. This is due to higher-order protein folding – the primary sequence folds back on itself into a secondary and tertiary structure and quaternary structures. The general purpose of our method was to develop and apply NMR spectroscopy as a higher-order structure assessment tool to mAbs. Our goal was to show that this technique could deliver data that demonstrate highly similar or fingerprint-like similarity between protein lots, or between an innovator and a biosimilar.

How did you make the method work?
Our goal as a lab is to push the practical limits of NMR spectroscopy. Within that framework, it was natural for us to attempt this type of characterization. We were pleasantly surprised, however, that we successfully collected data with such high quality on the intact mAb. We demonstrated that collecting the 2D 13C,1H NMR methyl fingerprint is feasible on the intact mAb. The methyl group has greater rotation than other functional groups, which leads to sharper peaks and therefore higher spectral quality. These groups are dispersed throughout the protein and directly report on how well the protein is folded. Since NMR systems with lower magnetic field strength are more commonly found in analytical research labs, we divided the mAb enzymatically into its two constituent Fc and Fab fragments, so that the NMR mapping approach could be employed using more commonly available NMR systems. Importantly, we demonstrated that the two fragments generated from the full mAb showed no loss of structural information and that the sum of the fingerprint patterns of the fragments could be matched to the intact mAb.

What are the implications for drug development?
This measurement technique provides a robust means for a company to characterize  the higher-order structure of a protein drug product. This is useful in pre-clinical and clinical settings as it shows where the drug is acting and why. In a QC environment, NMR could potentially be used to evaluate multiple lots through statistical comparability methods and compare biosimilars to innovator products.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. L.W. Abrogast, R.G. Brinson and J.P. Marino, “Mapping Monoclonal Antibody Structure by 2D 13C NMR at Natural Abundance,” Analytical Chemistry 87, 3556-3561 (2015). DOI: 10.1021/ac504804m

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

Electrifying R&D Acceleration
Small Molecules Analytical Science
Electrifying R&D Acceleration

December 2, 2014

0 min read

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings...

The Lab of the Future: Combining Automation with Digital Tools
Contract Development Services Analytical Science Technology and Equipment Digital Technologies
The Lab of the Future: Combining Automation with Digital Tools

February 25, 2025

6 min read

How do you scale up operations without adding headcount or significantly increasing investment in instrumentation? The answer: automation and workflow scheduling software.

SORS and the Power of Light in Pharma
Ingredients Analytical Science Technology and Equipment
SORS and the Power of Light in Pharma

January 17, 2025

7 min read

Understanding the role of spatially offset Raman spectroscopy in identifying raw materials, counterfeit medicines, and more

Facing Up to the New Nemesis of Pharma: Nitrosamines
Quality & Compliance Small Molecules Process Control Analytical Science Ingredients
Facing Up to the New Nemesis of Pharma: Nitrosamines

September 5, 2024

8 min read

What’s going on with nitrosamines in pharmaceutical products? Naiffer Romero, Principal Scientist at the US Pharmacopeia walks us through frequently asked questions.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.